Allergan

AbbVie to Sell off Allergan Women’s Health Portfolio

US pharma AbbVie has put compatriot Allergan’s women’s health business up for sale. The company is said to be working with Morgan Stanley on an auction process that has attracted interest from private equity firms including CVC Capital Partners. Reuters, which broke the story, said AbbVie’s existing women’s health franchise before picking up Allergan is not part of the sale.

US FTC Scrutinizes AbbVie/Allergan Deal

Injecting Growth and Innovation

Opioid Makers Angling to Settle out of Court

AbbVie to Buy Allergan for $63 Billion

Allergan Boosts Aesthetics with Bonti Buy

Pershing and Valeant Settle Allergan Lawsuits

Teva Confirms Massive Cost Cuts, Job Losses

Teva Cuts Jobs, Closes Plants as Woes Deepen

Allergan and Novartis Link on NASH

Allergan and Editas Medicine in Eye Disease Pact

Activist Investor Ackman Exits Valeant

Allergan Boosts Esthetics with Zeltiq Buy

Teva Facing Bribery Charges in Israel

Pharma Stocks Crash on Trump Pricing Hints

Allergan Buys US Chase Pharmaceuticals

Pfizer Loses Patent Appeal Against Allergan

Allergan Acquires Akarna Therapeutics

Allergan to Buy Tobira Therapeutics

Allergan Acquires Retrosense

Teva to Buy Anda from Allergan

Pharma Management Radar survey 2016: Escaping the complexity trap

Teva says Actavis Closing on Track

Allergan and Heptares in Neurological Drugs Deal

Pfizer and Allergan Bury Merger Plans

US Inversion Plan Could Scupper Pfizer-Allergan

FTC Looks Closer at Pfizer/Allergan Merger

EU Gives OK for Teva to Buy Allergan Generics

SEC Investigates Valeant Again

Leadership Team Named for Pfizer-Allergan

KPMG Expects 2016 to become Another Record Year for M&A in the Pharmaceutical Industry

Pfizer to Buy Allergan for $160 Billion

Mylan Bid for Perrigo Fails

Pfizer and Allergan in Merger Talks

Leaving the Patent Cliff Behind